Gene methylation as a powerful biomarker for detection and screening of non-small cell lung cancer in blood
Metrics: PDF 1189 views | HTML 1533 views | ?
Bao-hua Wang1,*, Yan-yu Li2,*, Jin-zhu Han3, Lian-ya Zhou1, Ying-qian Lv3, He-lin Zhang1 and Li Zhao3
1Department of Thoracic Surgery, The Second Hospital of Heibei Medical University, Shijiazhuang 050000, China
2Department of General Surgery, The Second Hospital of Heibei Medical University, Shijiazhuang 050000, China
3The Second Department of Oncology, The Second Hospital of Heibei Medical University, Shijiazhuang 050000, China
*These authors have contributed equally to this work
Ying-qian Lv, email: email@example.com
Keywords: gene methylation, NSCLC, blood, biomarkers
Received: August 15, 2016 Accepted: January 10, 2017 Published: March 06, 2017
DNA methylation has been reported to become a potential powerful tool for cancer detection and diagnosis. However, the possibilities for the application of blood-based gene methylation as a biomarker for non-small cell lung cancer (NSCLC) detection and screening remain unclear. Hence, we performed this meta-analysis to evaluate the value of gene methylation detected in blood samples as a noninvasive biomarker in NSCLC. A total of 28 genes were analyzed from 37 case-control studies. In the genes with more than three studies, we found that the methylation of P16, RASSF1A, APC, RARβ, DAPK, CDH13, and MGMT was significantly associated with risks of NSCLC. The methylation statuses of P16, RASSF1A, APC, RARβ, DAPK, CDH13, and MGMT were not linked to age, gender, smoking behavior, and tumor stage and histology in NSCLC. Therefore, the use of the methylation status of P16, RASSF1A, APC, RARβ, DAPK, CDH13, and MGMT could become a promising and powerful biomarker for the detection and screening of NSCLC in blood in clinical settings. Further large-scale studies with large sample sizes are necessary to confirm our findings in the future.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.